Recent News

• 09.11.2026 - GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
• 09.03.2026 - 8-K - Current report
• 08.14.2026 - 8-K - Current report
• 08.14.2026 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 08.14.2026 - GT Biopharma Reports Second Quarter 2026 Financial Results
• 07.28.2026 - CORRESP - Correspondence
• 07.28.2026 - UPLOAD - SEC-generated letter
• 07.02.2026 - DEF 14A - Definitive proxy statements
• 06.18.2026 - PRE 14A - Preliminary proxy statement not related to a contested matter or merger/acquisition
• 06.12.2026 - 8-K - Current report

Recent Filings

• 09.03.2026 - 8-K Current report
• 08.14.2026 - 8-K Current report
• 08.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.02.2026 - DEF 14A Other definitive proxy statements
• 06.18.2026 - PRE 14A Other preliminary proxy statements
• 06.12.2026 - 8-K Current report
• 05.22.2026 - 8-K Current report
• 05.15.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - EFFECT Notice of Effectiveness
• 05.13.2026 - 424B3 Prospectus [Rule 424(b)(3)]